By Tom Winnifrith | Monday 20 January 2014
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Speciality pharmaceutical company, Alliance Pharma (APH) last week announced that “turnover for 2013 is expected to be £45.5m (2012: £44.9m) and pre-tax profits are expected to be in line with current market expectations” (expectations are for earnings per share of around 3.5p) as well as an acquisition of the rights to the thyroid product Irenat in Germany from subsidiaries of Bayer AG.
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Time left: 07:57:46